Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 15-19

  Fiorino, Gionata ^a   Danese, Silvio ^a   Pariente, Benjamin ^b   Allez, Matthieu ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INSERM   (France)

Author keywords

Anti TNF; Autoimmunity; IBD; Paradoxical reactions

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRAIN DISEASE; COLITIS; CROHN DISEASE; DEEP VEIN THROMBOSIS; DERMATITIS; ECZEMA; GLOMERULONEPHRITIS; HUMAN; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MOUTH ULCER; MULTIPLE SCLEROSIS; MYALGIA; MYELITIS; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEIZURE; VASCULITIS;

ANTI-TNF; AUTOIMMUNITY; IBD; PARADOXICAL REACTIONS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886952283     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.005     Document Type: Review

References (35)

1. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
2. Ford A.C., Sandborn W.G., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
3. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2:CD008794.
4. Perez-Alvarez R., Pérez-de-Lis M., Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013, 25:56-64. BIOGEAS study group.
5. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
6. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
7. Rahier J.F., Buche S., Peyrin-Biroulet L., Bouhnik Y., Duclos B., Louis E., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8:1048-1055.
8. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
9. Flendrie M., Vissers W.H., Creemers M.C., de Jong E.M., van de Kerkhof P.C., van Riel P.L. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:666-676.
10. Fiorino G., Allez M., Malesci A., Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:921-927.
11. Collamer A.N., Guerrero K.T., Henning J.S., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
12. Dalkilic E., Bulbul Baskan E., Alkis N., Gullulu M., Yavuz M., Dilek K., et al. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod Rheumatol 2012, 22:738-742.
13. de Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
14. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
15. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20:100-108.
16. Wollina U., Hansel G., Koch A., Schönlebe J., Köstler E., Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
17. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012, 9:496-503.
18. Cullen G., Kroshinsky D., Cheifetz A.S., Korzenik J.R. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011, 34:1318-1327.
19. Buisson A., Cuny J.F., Barbaud A., Schmutz J.L., Bigard M.A., Guéant J.L., et al. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:1175-1180.
20. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205:2491-2497.
21. Ma H.L., Napierata L., Stedman N., Benoit S., Collins M., Nickerson-Nutter C., et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010, 62:430-440.
22. Rosenbaum J.T., Angell E. Paradoxical effects of IL-10 in endotoxin-induced uveitis. J Immunol 1995, 155:4090-4094.
23. Toussirot E., Houvenagel E., Goëb V., Fouache D., Martin A., Le Dantec P., et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 2012, 79:457-463.
24. van Dijken T.D., Vastert S.J., Gerloni V.M., Pontikaki I., Linnemann K., Girschick H., et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011, 38:1441-1446.
25. Noti M., Corazza N., Mueller C., Berger B., Brunner T. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 2010, 207:1057-1066.
26. Kojouharoff G., Hans W., Obermeier F., Männel D.N., Andus T., Schölmerich J., et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997, 107:353-358.
27. Naito Y., Takagi T., Handa O., Ishikawa T., Nakagawa S., Yamaguchi T., et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003, 18:560-569.
28. Wendling D., Paccou J., Berthelot J.M., Flipo R.M., Guillaume-Czitrom S., Prati C., et al. New onset of uveitis during anti-tumour necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011, 41:503-510.
29. Bosch X., Saiz A., Ramos-Casals M. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011, 7:165-172.
30. Brigo F., Bongiovanni L.G., Cerini R., Manganotti P., Storti M., Fiaschi A. Infliximab-related seizures: a first case study. Epileptic Disord 2011, 13:214-217.
31. Stubgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281-292.
32. Hommes D.W., Oldenburg B., van Bodegraven A.A., van Hogezand R.A., de Jong D.J., Romberg-Camps M.J., et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006, 64:219-229.
33. Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125:32-39.
34. Beigel F., Schnitzler F., Laubender P., Pfennig S., Weidinger M., Göke B., et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:91-98.
35. Subramanian S., Yajnik V., Sands B.E., Cullen G., Korzenik J.R. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011, 17:99-104.